HUMACYTE INC (HUMA) Fundamental Analysis & Valuation

NASDAQ:HUMA • US44486Q1031

Current stock price

0.607 USD
-0.04 (-6.83%)
At close:
0.6267 USD
+0.02 (+3.25%)
Pre-Market:

This HUMA fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

1

1. HUMA Profitability Analysis

1.1 Basic Checks

  • In the past year HUMA has reported negative net income.
  • HUMA had a negative operating cash flow in the past year.
  • In the past 5 years HUMA always reported negative net income.
  • In the past 5 years HUMA always reported negative operating cash flow.
HUMA Yearly Net Income VS EBIT VS OCF VS FCFHUMA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 2022 2023 2024 2025 -50M -100M

1.2 Ratios

  • HUMA has a Return On Assets of -35.09%. This is in the better half of the industry: HUMA outperforms 60.54% of its industry peers.
  • HUMA has a Return On Equity of -1313.38%. This is amonst the worse of the industry: HUMA underperforms 81.62% of its industry peers.
Industry RankSector Rank
ROA -35.09%
ROE -1313.38%
ROIC N/A
ROA(3y)-76.52%
ROA(5y)-48.93%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
HUMA Yearly ROA, ROE, ROICHUMA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 2022 2023 2024 2025 0 -500 -1K

1.3 Margins

  • The Profit Margin and Operating Margin and Gross Margin are not available for HUMA so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
HUMA Yearly Profit, Operating, Gross MarginsHUMA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 2022 2023 2024 2025 0 -2K -4K -6K

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

3

2. HUMA Health Analysis

2.1 Basic Checks

  • HUMA does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • HUMA has more shares outstanding than it did 1 year ago.
  • HUMA has more shares outstanding than it did 5 years ago.
  • HUMA has a better debt/assets ratio than last year.
HUMA Yearly Shares OutstandingHUMA Yearly Shares OutstandingYearly Shares Outstanding 2019 2020 2021 2022 2023 2024 2025 50M 100M 150M
HUMA Yearly Total Debt VS Total AssetsHUMA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2019 2020 2021 2022 2023 2024 2025 50M 100M 150M 200M 250M

2.2 Solvency

  • Based on the Altman-Z score of -10.66, we must say that HUMA is in the distress zone and has some risk of bankruptcy.
  • HUMA has a worse Altman-Z score (-10.66) than 73.50% of its industry peers.
  • HUMA has a Debt/Equity ratio of 20.08. This is a high value indicating a heavy dependency on external financing.
  • HUMA's Debt to Equity ratio of 20.08 is on the low side compared to the rest of the industry. HUMA is outperformed by 83.37% of its industry peers.
Industry RankSector Rank
Debt/Equity 20.08
Debt/FCF N/A
Altman-Z -10.66
ROIC/WACCN/A
WACC8.65%
HUMA Yearly LT Debt VS Equity VS FCFHUMA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2019 2020 2021 2022 2023 2024 2025 0 50M -50M 100M -100M

2.3 Liquidity

  • HUMA has a Current Ratio of 3.69. This indicates that HUMA is financially healthy and has no problem in meeting its short term obligations.
  • Looking at the Current ratio, with a value of 3.69, HUMA is in line with its industry, outperforming 45.26% of the companies in the same industry.
  • A Quick Ratio of 2.95 indicates that HUMA has no problem at all paying its short term obligations.
  • HUMA's Quick ratio of 2.95 is on the low side compared to the rest of the industry. HUMA is outperformed by 62.28% of its industry peers.
Industry RankSector Rank
Current Ratio 3.69
Quick Ratio 2.95
HUMA Yearly Current Assets VS Current LiabilitesHUMA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2019 2020 2021 2022 2023 2024 2025 50M 100M 150M 200M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

5

3. HUMA Growth Analysis

3.1 Past

  • HUMA shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 84.13%, which is quite impressive.
  • The Revenue has been growing slightly by 6.46% on average over the past years.
EPS 1Y (TTM)84.13%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%18.75%
Revenue 1Y (TTM)N/A
Revenue growth 3Y9.09%
Revenue growth 5Y6.46%
Sales Q2Q%N/A

3.2 Future

  • HUMA is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 107.00% yearly.
  • Based on estimates for the next years, HUMA will show a very strong growth in Revenue. The Revenue will grow by 220.56% on average per year.
EPS Next Y-127.8%
EPS Next 2Y-29.73%
EPS Next 3Y132.12%
EPS Next 5Y107%
Revenue Next Year343.06%
Revenue Next 2Y266.15%
Revenue Next 3Y258.89%
Revenue Next 5Y220.56%

3.3 Evolution

  • When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
HUMA Yearly Revenue VS EstimatesHUMA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 1B 2B 3B
HUMA Yearly EPS VS EstimatesHUMA Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 0 5 10

More info and screens

Find the best growth stocksShow best growing peers

1

4. HUMA Valuation Analysis

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for HUMA. In the last year negative earnings were reported.
  • Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for HUMA. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
HUMA Price Earnings VS Forward Price EarningsHUMA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30 40 50

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
HUMA Per share dataHUMA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -0.1 -0.2 -0.3 -0.4 -0.5

4.3 Compensation for Growth

  • HUMA's earnings are expected to grow with 132.12% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-29.73%
EPS Next 3Y132.12%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. HUMA Dividend Analysis

5.1 Amount

  • No dividends for HUMA!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

HUMA Fundamentals: All Metrics, Ratios and Statistics

HUMACYTE INC

NASDAQ:HUMA (4/9/2026, 8:00:02 PM)

Premarket: 0.6267 +0.02 (+3.25%)

0.607

-0.04 (-6.83%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)03-27
Earnings (Next)05-11
Inst Owners28.94%
Inst Owner Change0%
Ins Owners5.81%
Ins Owner Change2.24%
Market Cap117.15M
Revenue(TTM)2.04M
Net Income(TTM)-40.83M
Analysts81.54
Price Target8.01 (1219.6%)
Short Float %25.23%
Short Ratio5.54
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)17.55%
Min EPS beat(2)3.2%
Max EPS beat(2)31.89%
EPS beat(4)3
Avg EPS beat(4)58.51%
Min EPS beat(4)-45.54%
Max EPS beat(4)244.48%
EPS beat(8)4
Avg EPS beat(8)14.63%
EPS beat(12)7
Avg EPS beat(12)4.8%
EPS beat(16)10
Avg EPS beat(16)24.62%
Revenue beat(2)0
Avg Revenue beat(2)-42.94%
Min Revenue beat(2)-65.91%
Max Revenue beat(2)-19.96%
Revenue beat(4)0
Avg Revenue beat(4)-47.45%
Min Revenue beat(4)-70.58%
Max Revenue beat(4)-19.96%
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)6.94%
EPS NQ rev (3m)6.94%
EPS NY rev (1m)0%
EPS NY rev (3m)1.11%
Revenue NQ rev (1m)-45.69%
Revenue NQ rev (3m)-45.69%
Revenue NY rev (1m)-46.69%
Revenue NY rev (3m)-47.06%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 57.48
P/FCF N/A
P/OCF N/A
P/B 37.68
P/tB 37.68
EV/EBITDA N/A
EPS(TTM)-0.2
EYN/A
EPS(NY)-0.46
Fwd EYN/A
FCF(TTM)-0.55
FCFYN/A
OCF(TTM)-0.54
OCFYN/A
SpS0.01
BVpS0.02
TBVpS0.02
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -35.09%
ROE -1313.38%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-76.52%
ROA(5y)-48.93%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0.02
Health
Industry RankSector Rank
Debt/Equity 20.08
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 12.04%
Cap/Sales 43.38%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 3.69
Quick Ratio 2.95
Altman-Z -10.66
F-Score5
WACC8.65%
ROIC/WACCN/A
Cap/Depr(3y)21.15%
Cap/Depr(5y)15.78%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)84.13%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%18.75%
EPS Next Y-127.8%
EPS Next 2Y-29.73%
EPS Next 3Y132.12%
EPS Next 5Y107%
Revenue 1Y (TTM)N/A
Revenue growth 3Y9.09%
Revenue growth 5Y6.46%
Sales Q2Q%N/A
Revenue Next Year343.06%
Revenue Next 2Y266.15%
Revenue Next 3Y258.89%
Revenue Next 5Y220.56%
EBIT growth 1Y5.34%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year100.7%
EBIT Next 3Y38.81%
EBIT Next 5Y32.47%
FCF growth 1Y-6.25%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-7.05%
OCF growth 3YN/A
OCF growth 5YN/A

HUMACYTE INC / HUMA Fundamental Analysis FAQ

What is the fundamental rating for HUMA stock?

ChartMill assigns a fundamental rating of 2 / 10 to HUMA.


What is the valuation status for HUMA stock?

ChartMill assigns a valuation rating of 1 / 10 to HUMACYTE INC (HUMA). This can be considered as Overvalued.


What is the profitability of HUMA stock?

HUMACYTE INC (HUMA) has a profitability rating of 1 / 10.


What is the financial health of HUMACYTE INC (HUMA) stock?

The financial health rating of HUMACYTE INC (HUMA) is 3 / 10.


What is the expected EPS growth for HUMACYTE INC (HUMA) stock?

The Earnings per Share (EPS) of HUMACYTE INC (HUMA) is expected to decline by -127.8% in the next year.